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Conditional knockout mousehosphorylation system (OXPHOS) are responsible for a group of extremely
heterogeneous and pleiotropic pathologies commonly known as mitochondrial diseases. Although many
mutations have been found to be responsible for OXPHOS defects, their pathogenetic mechanisms are
still poorly understood. An important contribution to investigate the in vivo function of several mito-
chondrial proteins and their role in mitochondrial dysfunction, has been provided by mouse models.
Thanks to their genetic and physiologic similarity to humans, mouse models represent a powerful tool to
investigate the impact of pathological mutations on metabolic pathways. In this review we discuss the
main mouse models of mitochondrial disease developed, focusing on the ones that directly affect the
OXPHOS system.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMitochondrial disorders are a group of clinically heterogeneous
diseases and metabolic syndromes resulting from a dysfunction in the
oxidative phosphorylation (OXPHOS) system, the terminal component
of energy metabolism in the mitochondria of eukariotic cells. The
estimated prevalence for mitochondrial disorders is 1:5000 [1,2],
placing them among the most common genetically inherited diseases.
The majority of the cellular energy is produced in the form of ATP by
the OXPHOS, through the oxidation of organic substrates. The OXPHOS
requires the ﬁnely coordinated action of ﬁve multi-heteromeric
enzyme complexes embedded in the inner mitochondrial membrane
and of twomobile electron carriers, ubiquinone (Q) and cytochrome c.
Reducing equivalents, in the form of NADH and FADH2, mostly coming
from glycolysis and the Krebs cycle, enter into the mitochondrial
respiratory chain by complex I and complex II respectively. From there,
through sequential redox reactions, the electrons are translocated to
ubiquinone, complex III, cytochrome c, complex IV and ﬁnally
reducing molecular oxygen generating two molecules of water. The
electron ﬂow through the respiratory chain is coupled to an active
proton translocation across the inner mitochondrial membrane,
generated mostly by complexes I, III and IV. The inﬂux of the protons
back to the mitochondrial matrix through complex V (ATP synthase)
allows the phosphorylation of ADP into ATP [3,4].ool of Medicine, 1095 NW 14th
es).
l rights reserved.The biogenesis of the mitochondrial respiratory chain is extremely
complex as it is under the control of both the mitochondrial and the
nuclear DNAs (respectively mtDNA and nDNA). Only 13, of the
approximately 85 polypeptides, are encoded by mtDNA all of which
are integral subunits of the respiratory chain complexes. The rest of the
polypeptides are synthesized in the cytoplasm and targeted either co-
or post-translationally to the mitochondria [5,6]. Because of this
unique and intricate genetics, it is often difﬁcult to identify the etiology
of mitochondrial disorders [7]. Moreover, the limited availability of
human samples aswell as the paucity of large consanguineous families
suitable for linkage analyses, further complicates diagnosis. For all
these reasons, animal models are powerful tools, not only to better
understand the pathophysiology of mitochondrial disorders, but also
to develop effective therapies. In this review we will focus on several
mouse models of OXPHOS defects that have been created to date,
grouping them in three main categories according to the function of
the genes that have been manipulated (Table 1).
2. Mouse models for the study of nuclear-coded components of
the OXPHOS complexes
In contrast to the high number and well characterized mutations
detected in mtDNA (over 150, www.Mitomap.org), the number of
mutations affecting nuclear genes that have a pathogenic role in
mitochondrial diseases is relatively small. To better characterize the
role that some proteins might have in the assembly/stability or in the
function of the respiratory complexes, some investigators have
developed useful mouse models of OXPHOS dysfunction. Unfortu-
nately, to date, the only complex that has been extensively studied by
Table 1
Mouse models of OXPHOS defects
Group Modiﬁed
gene
Genetics Tissue affected Refs.
Nuclear-encoded components
of the OXPHOS complexes
COXVIa KO Heart [16]
Cox10 cd-KO Muscle [25]
Liver [30]
Brain [33]
Cyt c KO Testes [54]
Surf1 KO – [39]
Proteins involved in the
interaction and stability
of mtDNA
Tfam cd-KO
(rec)
Heart [79,80]
Skeletal muscle [83]
Pancreatic
endocrine
tissue
[84]
Brain [87,90,91]
Pol γ KI (dom) multiple [112,113,169]
Ant1 KO (rec) Skeletal
muscle, heart
[137]
Extraocular
muscle
[145]
Twinkle Transgenic
(dom)
Skeletal
muscle, brain
[131]
MTERF3 cd-KO Heart [99]
mtDNA defects 16S
rRNA
ES cybrid Skeletal
muscle, heart
[158]
Δ
mtDNA
Mito inject Skeletal
muscle, heart,
kidney
[159]
ND6ins/
COI
ES cybrid Skeletal
muscle, heart
[162]
cd-KO, KI, knockin conditional knockout; dom, dominant; rec, recessive; ES. embryonic
stem cell; mito inject, mitochondrial injection.
Fig. 1. Muscle pathology from Cox10 KO (muscle conditional) mice closely resembles
human clinical ﬁndings. Triceps surae muscle from 3-month-old mice was snap frozen
in isopentane cooled in liquid nitrogen. Serial cross sections of 8 µm thickness were
stained for cytochrome c oxidase activity, combined cytochrome c oxidase (COX) and
succinate dehydrogenase (SDH) activity, succinate dehydrogenase activity, Gomori
Trichrome stain and immunostained with Alexa conjugated COXI monoclonal antibody
to show the a COX deﬁciency and mitochondrial proliferation in muscles of the Cox10
knockout mice. The non-synchronous Cre deletion of the gene reproduces the mosaic
pattern observed in patients with mtDNA mutations.
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model for OXPHOS deﬁciencies have failed due to the embryonic
lethality, so the majority of the studies have been conducted in
conditional knockout (KO) mice.
2.1. Cytochrome c oxidase models
Mammalian cytochrome c oxidase (COX or complex IV) is
composed of 13 polypeptides, 3 of which are encoded by mtDNA
(COX I, II, III) and are part of the catalytic core of the enzyme. COX
biogenesis has been extensively studied in yeast and is the result of an
intricate process, implicating the cooperation of more than 20
additional nuclear encoded proteins [8]. Isolated defects of COX are
the most frequent causes of Leigh syndrome (LS), which is a subacute
necrotizing encephalomyelopathy. Despite the large number of
proteins involved in the formation of the holoenzyme, no mutations
have been found in the nuclear encoded structural components of
COX, but only in proteins involved in its assembly, such as: Surf1,
COX10, COX15, SCO1, SCO2 and LRPPRC [9–15].
To address the question of whether structural nuclear encoded
proteins could have a protective role by shielding the catalytic core of
the enzyme, Radford and colleague have developed a mouse in which
the nuclear encoded subunit CoxVIaH was knocked out [16]. In
mammals, the CoxVIa subunit is present in two isoforms, heart (H)
and liver (L) [17]. During fetal life, the L form is predominant and
ubiquitously expressed whereas, after birth, the H isoform completely
replaces the former one in striated muscle [18]. The CoxVIaH KO
(CoxVIaH−/−) mice displayed a reduction in COX activity to about 23% of
the controls. Still, the mice were viable and showed a normal life span.
Phenotypically, CoxVIaH−/− mice developed a speciﬁc myocardial
diastolic dysfunction, but the pathogenic mechanisms leading to this
phenotype have not been clariﬁed. CoxVIa contains a binding site
“sensor” for adenine nucleotides and the level of ATP/ADP can
modulate the activity of COX [19]. However, in this model, thedisruption of CoxVIa did not affect the activity of COX, as there was no
difference in the levels of ATP in the heart of CoxVIaH+/+, CoxVIaH+/−
and CoxVIaH−/− mice. Conversely, a reduction in the levels of fully
assembled complex has been detected in the null mice, suggesting a
role for this subunit in the assembly/stability of COX rather than in its
regulation.
Although several mutations have been described in assembly
factors of COX their pathogenic role in humans is still poorly
understood. An extensive study, using mouse models, has involved
two of the maturation/assembly proteins involved in the biogenesis of
COX, namely, COX10 and Surf1. The product of COX10 is a protoheme:
heme-O-farnesyl transferase, involved in the biosynthesis of heme a,
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inner mitochondrial protein encoded by a gene containing 7 exons
[20]. Mutations of COX10 have been associated to leukodystrophy and
tubulopathy, anemia and Leigh syndrome, sensorineural deafness and
fatal infantile hypertrophic cardiomyopathy [11,21,22]. The conse-
quences of a Cox10 disruption in muscle has been evaluated by Diaz et
al. who developed a conditional muscle KO. Exon 6 of Cox10 was
deleted using the Cre–LoxP system [23], using a Cre recombinase
driven by the myosin light chain 1f promoter (mlc1f) [24]. The
resulting Cox10 KO mice showed a marked reduction in COX activity
(about 13% of the control mice) in skeletal muscle at 1 month of age,
but no signs of a myopathy were evident until 2.5–3 months [25]. The
deﬁciency progressed with the age of the animals, eventually
developed a severe myopathy with features that were similar to the
ones observed in patients [26]. At 6–7 months, the COX activity in the
Cox10 KO mice was approximately 3% of the controls. There was a
mosaic pattern of COX deﬁciency in muscle, resembling the pathology
associated with mitochondrial myopathies due to mtDNA mutations
(Fig. 1). There was a reduction of the fully assembled COX, but no
subassemblies were detected [25]. A gender bias in terms of exercise
tolerance, life span and survival was observed as males performed
better than females and lived longer. A possible explanation for this
phenomenon would be the increase in the muscle mass triggered by
testosterone. It has been shown that estrogen and progesterone can
modulate the transcription levels of genes conferring resistance to
oxidative stress and sustaining energy demands [27,28]. Thus, it can be
assumed that a similar effect might be occurring in skeletal muscle.
The genetic background represents another factor that may affect the
penetrance of the disease [29]. The effect of the ablation of Cox10 has
also been evaluated in liver [25] by crossing homozygous Cox10 ﬂoxed
mice with transgenic mice expressing a liver speciﬁc Cre recombinase,
under the control of the rat albumin promoter (Alb-Cre) [30]. For this
study two different progenies were analyzed: K1, homozygous for the
ﬂoxed allele and hemizygous for Cre and K2, which were homozygous
for both ﬂoxed allele and Cre. Although a severe decrease in COX
activity was observed in both K1 and K2 mice at 56 days of age, few
hepatocytes escaped Cox10 ablation and only K2 mice developed a
more severe phenotype characterized by hepatomegaly and steatosis
and premature death at 60 days of age. Accordingly, COX activity was
lower in K2 when compared to K1. At 56 days of age a signiﬁcant
decrease in glycogen, glucose and ATP levels were observed in both K1
and K2 animals, but at older ages (over 70 days) a progressive recovery
of these energy sources was observed in the K1 animals. Other
markers of liver injury were measured and all of them followed the
same trend: there was a progressive increase of liver enzymes in the
serum after 23 days of age that worsened for K2 mice and switch to
nearly normal levels for the older K1 mice [30]. All these metabolic
recoveries paralleled the increase in the number of COX positive cells
observed in several liver biopsies in K1 mice at different ages.
Somehow, hepatocytes with an intact Cox10 proliferated and
repopulated the defective liver. It is interesting to highlight that this
mouse model showed that hepatocytes could survive over 60 days
with an impaired OXPHOS before undergoing an apoptotic process,
possibly by using the glycolysis/glycogenolysis as an energy source.
Regarding the differential expression of Alb-Cre recombinase, Schulz
et al. showed that Alb-Cre can undergo a total lost in the expression of
the transgene with increasing number of generations, leading to an
incomplete ablation of the ﬂoxed gene [31]. The reason why this
occurs might be due to a random integration of the transgene in
genomic regions that can cause silencing of the gene [32].
To investigate the role of COX deﬁciency in neurodegenerative
disorders, Fukui et al. have developed a conditional Cox10 KO mouse
in the brain of an Alzheimer's disease (AD)mousemodel [33]. The COX
deﬁciency cause by the CamKII α-Cre led to a progressive neurode-
generation, starting at approximately 4 months. One of the hypoth-
eses for the developing of AD is that the extracellular deposition of β-amyloid (Aβ) plaques might be an initiating factor for AD [34,35].
These plaques are formed by the successive cleavage of the amyloid
precursor protein (APP) by two different proteases, β-secretase and
the complex γ-secretase/presenilins. AD mice carrying a mutant form
of APP and presenilin (PSEN1) have beenwell characterized [36]. They
accumulate amyloid plaques without showing behavioural abnorm-
alities. Hemizygous AD and homozygous Cox10 ﬂoxed mice were
crossed with homozygous Cox10 ﬂoxed and hemizygous CamKIIα-Cre
[37] mice and the resulting Cox10 deﬁcient (COXd)/AD mice were
characterized. In 4-month-old COXd/AD mice, when the effects of the
COX deﬁciency in neuronal numbers is still not observed, there was a
reduction in the number of amyloid plaques and in the amount of
Aβ42, in cortex and hippocampus, and a reduction of the β-secretase
activity, in cortex, when compared to AD mice [33]. The evaluation of
oxidative stress markers in these mice showed also a reduction in the
level of protein carbonyls and oxidative damage of nucleic acid. The
authors concluded that the COX deﬁciency does not promote oxidative
stress and it is probably a consequence of the intracellular accumula-
tion of Aβ [33].
The other COX assembly factor for which mouse models have been
described is Surf1 [38,39]. Surf1 is the ﬁrst nuclear encoded protein
where mutations have been found in patients with isolated COX
deﬁciency [9,10]. In most cases, mutations in Surf1 are associated with
Leigh syndrome [9]. The function of this protein is still not well
understood in mammals, but the lack of the protein causes impair-
ment in the assembly of the COX holoenzyme [40,41]. In yeast, the
function of its homologue, Shy1, has been better characterized [42–
44]. In mouse, the Surf1 gene is located in the surfeit locus on
chromosome 2 [45]. In the ﬁrst Surf1 KOmouse generated by Agostino
et al. a targeting vector containing a neomycin cassette replaced exons
5–7 in the Surf1 gene [38]. Most of the KO pups died during
development and among the ones that were born, the authors
observed a wide variability in viability. A gender bias was observed in
the KO mice with a higher percentage of male pups dying within the
ﬁrst 2 months. Phenotypically, the KO pups were smaller than the wt
littermates and the most severe clinical symptoms were manifested
only 24 h before death [38]. Embryonic lethality was observed also in
Drosophila melanogaster where Surf1 was knocked down. However,
the authors attributed the lethality to the neomycin insertion rather
than directly to the ablation of Surf1. This hypothesis was conﬁrmed
by a subsequent Surf1 KO mouse model, in which the neomycin
cassette was targeted to the exon 7, disrupting only the last portion of
the gene [39]. After the excision of the neomycin cassette, the
resulting Surf1−/−micewere viable and the adults were phenotypically
normal. The decrease in COX activity in tissues was mild and
comparable with the levels measured in the previous Surf1 KO
model [38]. Unexpectedly, a longer life spanwas observed in the Surf1
KO mice. Stress-induced neuronal damage by kainic acid, an
epileptogenic glutamate agonist [46], showed an increase resistance
to neuronal death induced by Ca2+ inﬂux in KO neurons compared
with the controls. Apoptosis was marked in the control animals and
absent in the KO mice. Further experiments on 7-day-old cortical/
hippocampal primary neuronal cell cultures conﬁrmed the protective
role that the ablation of Surf1 conferred to KOmice. By treating Surf1−/
− and and Surf1+/+ neurons with high doses of glutamate, that are
known to irreversibly deregulate Ca2+ homeostasis in cells leading to
death [47], the authors observed a decrease in mitochondrial Ca2+
uptake in KO cells, possibly because a more limited capacity of mutant
mitochondria to buffer Ca2+. The role of membrane potential in the
susceptibility to apoptosis was assessed, but yielded no correlation.
Both the Surf1−/−and the Surf1+/+ had normal mitochondrial mem-
brane potential suggesting that Surf1 might be involved both in COX
assembly and in some other pathways responsible for the neuropro-
tective effects observed in vivo. A similar effect of impairing energy
metabolism on lifespan has beenwell documented for a set of genes in
Caenorhabditis elegans [48].
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Despite being just a single small protein, cytochrome c (cyt c) plays
a pivotal role in the cellular physiology since it has dual critical
functions, in energy metabolism and in programmed cell death [49].
As a component of the mitochondrial respiratory chain cyt c acts as an
electron carrier, localized in the inner membrane space, by driving
reduced equivalents from complex III to complex IV. When internal or
external stimuli activate the signals for apoptosis, cyt c is released
from the intermembrane space and, once in the cytosol, it binds the
proapoptotic factor Apaf1 [50]. The oligomerization of Apaf1 triggers
the activation of caspase 9 and downstream caspases 3, 6 and 7 [51].
Mammals have 2 isoforms of cyt c, a somatic and a testis one
(respectively cS and cT). Inactivation of cyt cS in mice causes embryonic
lethality, possibly due to the impairment of the respiratory chain [52].
The embryonic cells derived from this null mice displayed resistance
to stress-induced apoptosis, with a reduction in the activation of
caspase 3. In contrast, the cyt cS−/− cells remained highly sensitive to
tumor necrosis factor alpha (TNF-α) induced apoptosis [52].
The dual role of cyt c has been further conﬁrmed by a knock-in
mouse model in which only one amino acid residue (lysine 72)
responsible for the binding with Apaf1 was mutated [53]. The
resulting homozygous mice were born with a much lower frequency
than expected, indicating a partial embryonic lethality. Analysis of the
mutant embryos at E14.5 showed impairment of the central nervous
system (CNS) with typical signs shared with Apaf1−/−, caspase 3−/− and
caspase 9−/− mice, such as overgrowth of cortical matter. Experiments
conducted on cells derived from knock-in and control mice conﬁrmed
the speciﬁc role of the mutated amino acid for the function of the
protein, since the respiration and the release of cyt c were preserved.
However, the knock-in cells showed resistance to various apoptotic
stimuli [53]. Morphological examination of the surviving knock-in
mice showed a dramatic loss of neurons in the cortex and a reduction
in size of the thalamus and hypothalamus, but no caspase activation
was detected. A reduction in the number of cells in lymphoid tissues,
like thymus and spleen, was observed as well, albeit the authors were
not able to demonstrate a clear link between the tissues affected.
Mice lacking the testis isoforms of cyt cT displayed atrophy of the
testes and reduced number of spermatocytes, spermatids and
spermatozoa [54]. Surprisingly, the mice were still able to produce
spermatozoa but their motility was drastically reduced compared to
the controls, probably due to the reduction of ATP levels.
To better address the question whether cells with an impaired
OXPHOS gain resistance to apoptotic stimuli, Vempati et al. created a
double KO mouse inwhich both the somatic and the testis isoforms of
cyt c were disrupted [55]. Studies conducted on ﬁbroblasts derived
from the double KO mouse showed a total lack of respiration and a
resistance to both intrinsic and extrinsic apoptotic stimuli, in contrast
toTNF-α hypersensitivity observed in cyt cS−/− cells previously reported
[52]. A possible explanation might be the presence, in the early
passages of cyt cS−/− cells, of a small but active pool of cyt cT that is not
enough to sustain respiration but to confer the observed sensitivity to
TNF-α induced apoptosis is related to the respiratory dysfunction. Bcl-
xL overexpression was able to protect both a respiration-competent
and deﬁcient cell line against TNF-α, supporting an important role for
the mitochondria OXPHOS in amplifying death signals [55].
3. Mouse models for the study of proteins involved in the
interaction and stability of mtDNA
Mammalian mtDNA is a minicromosome of 16.5 kb that does not
undergo bi-parental recombination and is exclusively maternally
transmitted. There are about 103 copies of mtDNA per cell [56]. The
mutational rate of mtDNA is much higher than the nuclear DNA [57]
because of its structural organization and location. Studies in yeast
have demonstrated that mtDNA is organized in nucleoids, which arediscrete complexes of mtDNA and proteins [58,59] and that the same
discrete organization is also present in mammals [60]. The nucleoids
are anchored to the inner mitochondrial membrane, in close
proximity to the OXPHOS system, and so, exposed to reactive oxygen
species (ROS) generated by the electron transport chain. In contrast to
nDNA, mutations can easily affect mtDNA coding sequences either
because of the lack of introns or because the repairing systems are not
very efﬁcient in all cell types [61]. When mutations occur, mutated
and wt mtDNA can coexist in the same cell, a condition called
heteroplasmy [62]. In this condition, there is a particular threshold
mutation level required for the manifestation of the biochemical
defect in single cells. Thus, in a tissue, a mosaic pattern of respiratory
competent and deﬁcient cells can be observed. Mitochondrial
replication, transcription and translation occur in a semi-autonomous
fashion since the mitochondrion does not contain all the proteins
necessary for these processes and most are imported from the
cytoplasm [63,64]. Several polypeptides involved in maintenance of
mtDNA copy number have been associated with severe pathologies in
humans [65,66]. In the last decade, mouse models with disruption in
one of these factors have given valuable insights into the pathogenic
mechanism deriving from their dysfunction.
3.1. Tfam
Tfam, a protein involved in mtDNA maintenance, has been
extensively studied using mouse models. Tfam is a high-mobility
group (HGM)-box protein that binds the d-loop region of mtDNA, to
both the light and heavy strand promoters, and promotes the
transcription in vitro and in organello [67–69]. The function of Tfam
in vivo is still controversial since there is evidence supporting the
involvement of Tfam both in the transcription machinery [70] of
mitochondria and in the maintenance/stability of mtDNA [71]. An
important contribution about the role of Tfam came from the
extensive studies conducted by Larsson et al. who developed germ
line and conditional KO mouse models of Tfam. They demonstrated
that the presence of Tfam is critical for the normal embryogenesis,
since the lack of Tfam in the mouse germ line results in an arrest in
embryonic development between E8.5 and E10.5, caused mostly by
the total depletion of mtDNA and the consequent reduction in the ATP
levels [72]. Reduction of mtDNA amount, as a consequence of the
absence of Tfam, has also been shown in other species, such as Dro-
sophila and chicken, highlighting the evolutionary conserved role for
Tfam [73,74]. The linear correlation between Tfam and the amount of
mtDNA has been conﬁrmed by the analysis of heterozygous (Tfam+/−)
mice. In this case, the level of mtDNA dropped to 50% in several tissues
when compared to control animals, albeit only in the heart therewas a
proportional decrease in mitochondrial transcript levels. This obser-
vation suggests that there might be a temporary stabilization of
mRNAs in other tissues to compensate the mtDNA depletion, which
might delay the manifestation of the respiratory deﬁciency. Further
conﬁrmation of the linear correlation between Tfam and the mtDNA
amount comes from studies in which Tfam has been overexpressed. It
has been shown in different species that, by modulating the
expression levels of Tfam, there is a proportional variation in the
amount of mtDNA [71,75]. The mechanism by which this occurs is not
clearly understood, but a growing body of evidence suggests that Tfam
might be involved in the nucleoid formation thus stabilizing mtDNA
[76–78]. In vitro, human Tfam has a strong afﬁnity for mouse mtDNA
binding sites but is not able to start transcription [71].
Ekstrand et al. have provided evidence that the overexpression of
human Tfam in transgenic mice (Tg+) caused an increase in the
amount of mtDNA in all the tissues examined, without a relative
increase in the mitochondrial transcript levels. Also the mitochondrial
mass and volume in the transgenic micewere normal, conﬁrming that
Tfam does not increase mtDNA expression. The speciﬁc action of
human Tfam on the mtDNA copy number was strongly supported by
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lethalitywas still dominant after E10, affecting both Tfam−/− and Tfam−/−,
Tg+ genotypes, the analysis of the rescued embryos at E8.5–E9.5
showed an increase in the amount of mtDNA to about 30% of the wt
mtDNA level.
The consequences of Tfam disruption were also evaluated in a
tissue speciﬁc manner, through the generation of a large number of
conditional KO mice. Two different KO mouse models in the heart
have been developed by crossing homozygous Tfam−/− mice with
transgenic mice expressing two different cre recombinases. The
different cre expression allowed the investigators to have a temporal
control on the ablation of Tfam, evaluating the consequences during
embryonic development and after birth. In both cases, Tfam−/− mice
developed dilated cardiomyopathy in conjunction with cardioventri-
cular conduction blocks [79,80]. Overall, the pathological pattern was
the same than the one observed in mitochondrial cardiomyopathy,
characterized by tissue speciﬁc pattern of the OXPHOS defect,
progression of the onset paralleled by the decrease in the activity of
the OXPHOS, mosaicism of the respiratory deﬁcient cells in the
affected tissues [81,82]. Similarly, a typical picture of mitochondrial
myopathy was observed in a conditional KO mouse model in skeletal
muscle [83]. Morphological analysis showed different muscle ﬁber
size and numerous ragged red ﬁbers (RRF), due to an abnormal
subsarcolemmal accumulation of mitochondria, typical signs of a
mitochondrial myopathy. The histological examination demonstrated
the presence of several COX deﬁcient ﬁbers and, ultrastructural
evaluation of the Tfam KO ﬁbers showed an increase in mitochondrial
mass, considered as a compensatory mechanism for the deﬁcit of ATP
production.
Consequences of Tfam ablation were explored in the pancreatic
endocrine tissue [84], one of the loci that has been reported to be
affected bymitochondrial dysfunction [85,86]. In thismodel, Tfamwas
speciﬁcally deleted in the pancreatic β-cells by the expression of Cre
recombinase under the rat insulin-2 promoter (RIP-cre). Tfam−/− β-
cells had a dramatic depletion of mtDNA with a resulting loss of
respiratory function at 7 weeks of age and a consequent reduction in
insulin secretion. These Tfam conditional KO animals showed many
characteristics of mitochondrial disease associated with diabetes
mellitus, in particular the gradual development of insulinopenia and
the accumulation of β-cells damage with aging.
In the ‘mitochondrial late-onset neurodegeneration’ (MILON)
mouse [87], Tfam was selectively disrupted in neocortex and
hippocampus by a cre recombinase under the control of CaMKII
promoter. The MILON mice (Tfam−/−) showed signs of neurodegenera-
tion at about 4–5 months of age, although the recombination of the
ﬂoxed allele reached the maximal efﬁciency 1 month after birth.
Neurons from 5–6-month MILON mice were more sensitive to
exocitotoxic stimuli induced apoptosis but no activation of caspases
3 or 7 was detected and there was no variation in the level of Bax and
Bcl-xL compared to control animals suggesting other possible
apoptosis pathway involved in the neurodegeneration [87]. In contrast
to what is observed in patients with neurodegenerative disease [88],
no ROS species were detected in MILON brains [87]. The delay in the
manifestation of the disease as well as the uneven distribution of the
respiratory deﬁcient cells shares common features with neurodegen-
erative pathologies due to mtDNA mutations. More recently, this
model showed that affected neurons inﬂuence non-affected ones. This
trans-neuronal degeneration is based on the concept that neurons are
connected in trophic units [89] in the CNS. Starting from this
assumption, it is likely that the respiratory impaired neurons might
slowly affect, by a negative trophism, the surrounding normal
neurons, eventually leading them to death. The hypothesis was
supported by the development of a chimera MILON mouse carrying
both Tfam−/− and the wt (Tfam+) alleles in the brain [90]. According to
this model, symptoms started to appear in chimera when the
contribution of Tfam−/− cells was higher than 20%, suggesting thatup to this point the deleterious effects of the mutationwere mitigated
by the prevalence of the amount of wt cells (Tfam+). Only when the
contribution of Tfam−/− cells was higher than 60% the mice died from
massive neurodegeneration.
The picture of the CNS impairment due to the inactivation of Tfam
has been extended by the description of a conditional KO Tfammouse
[91] expressing cre recombinase under the control of the dopamine
transporter (DAT) promoter [92]. The resultingmice (MitoParkmouse)
manifested the typical traits of Parkinson disease (PD), characterized
by speciﬁc and progressive loss of dopaminergic neurones, starting
around 12 weeks of age, and progressive manifestation of reduced
locomotor capacity and tremor with aging. Affected neurons had Lewy
bodies-like inclusions, similar to the ones found in the brain of PD
patients [93]. A more accurate analysis of the intraneuronal inclusions
showed the absence of α-synuclein, a main component of the Lewy
bodies, and the presence of mitochondrial membranes and proteins,
suggesting a role of the inactive mitochondria in the genesis of the
disease [91].
3.2. MTERF3
MTERF3 is a newly identiﬁed mitochondrial protein [94] belonging
to the mitochondrial termination factors (mTerf) family. The best
known member of this family is MTERF1 that binds the 3′-end of the
rRNA cluster promoting the termination of the transcription [95,96].
More recently, it has been shown that it might participate also in the
initiation [97] and the regulation ofmtDNA transcription [98]. The ﬁrst
evidence about the role of Mterf3 in vivo was provided by a mouse
model developed by Park et al. [99]. HomozygousMterf3mice died in
utero before E10.5. The gene was subsequently conditionally deleted
in muscle and heart. The resulting KO mice developed cardiomegaly
due to mitochondrial impairment and died prematurely, around
18 weeks. The progressive reduction of MTERF3 did not affect the total
amount of mtDNA but, surprisingly, an increase in mitochondrial
transcripts was observed, suggesting a role in the suppression of
transcription.
3.3. Pol γ
There are a total of 15 cellular DNA polymerases identiﬁed so far
and only one, DNA polymerase gamma (Pol γ), is present in
mitochondria [100]. In humans, Pol γ is a heterodimer composed of
a catalytic subunit and an accessory DNA binding factor that confers
high processivity [101,102]. To date, almost 90 different mutations
have been reported in the pol γ gene that may be transmitted in either
a dominant or a recessive way (Human Polymerase Gamma Database,
http://dir-apps.niehs.nih.gov/polg). The mutations are associated with
a broad spectra of diseases [103], all of them characterized by
instability of mtDNA [82,104–106]. An accumulation of somatic
mtDNA mutations, with a consequent decline of the mitochondrial
function, is thought to be one of the causes of aging. Early in the 80s,
the theory of aging proposed that reactive oxygen species could
trigger the process by damaging mtDNA. These would accumulate
during life, leading eventually to cell death [107]. It has been shown
that mice lacking JunD, a factor involved in the antioxidant defence,
have a shorter life span compared to the controls [108]. Similarly,
overexpression of scavenger enzymes of ROS both in Drosophila or in
mouse, increases the life span and reduces the level of mtDNA damage
[109,110].
Nonetheless, the role of ROS as a major cause of aging has been
lately weakened by a number of in vivo observations, which were
reviewed in [111]. The so called “mutator mouse” negates the idea that
somatic mtDNA mutations are necessarily associated with ROS. The
mutator mouse has been generated by knocking-in Pol γ A, the
catalytic subunit of Pol γ, by changing a critical amino acid residue
(D257A) important for the exonuclease activity of the enzyme [112].
176 A. Torraco et al. / Biochimica et Biophysica Acta 1793 (2009) 171–180The mutator mice (Pol γ AD257A/D257A) were normal until 25 weeks of
age, after which they started to show premature aging associated with
alopecia (hair loss), kyphosis (curvature of the spine), loss of weight
and osteoporosis. The global phenotype of the mutator mice has
features of aging also observed in humans. The median life span of the
mutator mice was around 45 weeks whereas the controls lived much
longer (over 2 years) [112]. Interestingly, sequence analysis of mutator
mice revealed a high proportion of mtDNA mutations when
compared to the controls and an overall decrease in the mtDNA
content. ROS were not detected. Further evidence against the theory
of aging were provided by Kujoth et al. who showed that, the
premature aging in the mutator mouse, was not due to an increase in
ROS production and their “vicious cycle”, but due to an increase in the
apoptosis [113]. They showed that, in a 3-month-old Pol γ D257A/D257A
mouse, there was an earlier activation of caspase 3 in mitotic tissues
such as: duodenum, liver, testis and thymus. In post mitotic tissues
(skeletal muscle and brain), the activation of caspase 3 was evident
only when mice were 9-month-old, suggesting a higher resistance
of these tissues to apoptosis stimuli. This model represented the
ﬁrst direct evidence of the primary role that the accumulation of
mtDNA mutations plays in aging. However, it cannot be ruled out
that in humans, the aging process occurs in a different way since
targeted overexpression of the mutant human Pol γ (Y955C) in
mice's heart, causes accumulation of mtDNA mutations and ROS
production [114].
Another key information obtained from the mutator mouse is the
importance of mtDNA replication during embryogenesis. By totally
disrupting Pol γ A in the mouse germ line, an arrest in embryo
development occurs between E7.5 and E8.5 [115]. The Pol γ A−/−
embryos had a severe respiratory insufﬁciency due to the nearly lack
of mtDNA. Conversely, the amount of mtDNA in Pol γ A+/− mice was
the same as the controls demonstrating that there is no a gene-dosage
effect for Pol γ A as seen in Tfam+/− mice [72]. These data were
supported by the observation that the overexpression of Pol γ A does
not result in a parallel increase in the amount of mtDNA [116].
Moreover, themono allelic expression of Pol γ A is sufﬁcient to sustain
the minimal requirement of the respiratory function during the
critical developmental stage (between E7.5 and E8.5) when the
replication of mtDNA has to start again for the organogenesis [117,118].
One of the aging features displayed by all aging mouse models
described above is presbycusis, that is an age related hearing loss. It
has been reported that the incidence of presbycusis in aged people is
very high in the most developed countries [119] and, although the
mechanisms responsible for the progressive loss of hearing function
are not well understood, increased amount of evidence points to a
possible involvement of mitochondria as a cause of the disease [120–
123]. More details on this topic have been provided by cochlear
analysis conducted in Pol γ AD257A/D257A mouse [124]. The authors
showed that the impairment of Pol γ A caused loss of spiral ganglion
cells as well as of outer and inner hair cells in 9-month-old Pol γ
AD257A/D257A mice as observed in human pathologies [125,126].
Notably, the published data on the mutator mice did not give any
information about neuropathological examinations that are a hall-
mark of neurodegenerative diseases linked to aging, leaving open the
possibility of a different neurodegenerationmechanism existing in the
two species.
3.4. Twinkle
Twinkle is a mitochondrial hexameric helicase required for the
replication of mtDNA. It shares high similarity with the bacteriophage
T7 gene 4 protein (gp4) and has been shown to bind both single- and
double-strand DNA [127]. Mutations in Twinkle have been associated
with autosomal dominant progressive external ophtalmoplegia
(adPEO) [128], recessively inherited infantile onset spinocerebellar
ataxia (IOSCA) [129] and, recently, with early onset encephalopathyand liver involvement [130]. Common feature of all these diseases is
the resulting instability of mtDNA (depletion/deletions) due to the
impairment of the replication machinery.
Transgenic mice, overexpressing a mutant twinkle were viable and
showed a normal phenotype at all ages [131]. Mitochondrial
deﬁciency became manifested in 1-year-old mice. Analyses of the
muscle showed presence of COX negative ﬁbers, mitochondrial
proliferation at 18 months and the presence of abnormal ﬁber sizes
at 22 months. Nevertheless, only a mild decrease in COX activity was
detected. COX negative cells were found also in several brain regions
of 18-month-old animals. Molecular analysis of mtDNA revealed
multiple deletions both in the brain and in muscle of 18-month-old
mice and depletion of the total amount of mtDNA in the brain.
Exercise performance was not affected in the transgenic mice.
Interestingly, the accumulation of deleted mtDNA in this mouse
model did not result in premature aging as observed in Pol γ mice
[112,113].
3.5. Ant1
Although not a component of the OXPHOS system, adenine
nucleotide translocator (Ant) is critical for the ATP supply of the cell.
Ant is a transmembrane protein embedded in the inner mitochondrial
membrane. As homodimers, it mediates the exchange of ATP/ADP
between cytosol and mitochondria [132]. Three different isoforms
have been identiﬁed, Ant1, Ant2, Ant3, with different expression
patterns and presumably different functions [133]. Ant1 is also
involved in the formation or regulation of the mitochondrial
permeability transition pore (MPTP) [134,135], a structure that
participates in the early steps of cell death-mediated apoptosis.
Mutations in Ant1 have been linked to severe mitochondrial
pathologies associated with mtDNA instability [136].
The essential role played by Ant1 in energy homeostasis has been
demonstrated by its inactivation in a mouse model [137]. The
disruption of Ant1 in the germ line did not cause arrest during
embryogenesis and the mice were viable and healthy up to 8 months
of age. Subsequently, they started to manifest the disease in skeletal
muscle and heart, where Ant1 is mostly expressed. Morphological,
histochemical and ultrastructural analysis showed typical traits of
mitochondrial myopathy, characterized by mitochondrial prolifera-
tion, mosaicism of COX negative ﬁbers and abnormal mitochondria.
The general metabolic proﬁle of the Ant1−/− mice was reminiscent of
that in patients withmitochondrial disease, with high levels of lactate,
intermediates of the Krebs cycle and alanine in blood [138]. Ant1−/−
mice displayed severe exercise intolerance and fatigue [137] and, as
was observed in themuscle conditional Cox10 KOmodel, a gender bias
has been found, with females being more affected. The Ant1−/− mouse
provided evidence that depletion of ATP in the cells and dysfunction of
the OXPHOS was responsible for high levels of ROS production [139].
Concomitant upregulation of the antioxidant expression, in particular
manganese superoxide dismutase (SOD2) and glutathione peroxidase
(Gpx1), was detected in the tissue with high ROS production. The total
level of mtDNA in the skeletal muscle of Ant1−/− mice was highly
increased, in agreement with the increased number of mitochondria
in that tissue. Detection of mtDNA rearrangements showed the
presence of several mtDNA deleted species in the heart of middle-
aged mice (16–20-month-old) that was comparable to the amount
found in much older control animals (32-month-old). However, the
ROS-induced damage of mtDNA is not the sole possible explanation. In
humans, Ant1 dysfunction indirectly affects mtDNA stability by
disturbing intramitochondrial deoxinucleotide triphosphate (dNTP)
pool, thus causing an increase in the error rate of the mitochondrial
Pol γ [140,141]. The resulting deleted mtDNA molecules might have
replicative advantage over the normal molecules in post mitotic
tissues, as observed in the heart of Ant1−/− mice, resulting in a strong
decrease in the respiratory capacity.
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pathology, there might be other mechanisms besides ROS production
that can contribute to the damage of mtDNA. This speculation is
supported by the consideration that inactivation of Ant1 in yeast
causes damage of mtDNA molecules not paralleled by increase in ROS
production [142]. As a component of the MPTP, a possible alteration of
the apoptotic process was expected. However, a subsequent study,
where both Ant1 and Ant2 were disrupted in liver, showed that MPTP
was still functional [143].
Since one of the consequences of Ant1 mutation in humans is the
development of ophtalmoplegia [144], the inactivation of Ant1 has
been investigated speciﬁcally in the extraocular muscle (EOM) [145].
Although hallmarks of mitochondrial myopathy were evident, no
variation in eye movements was observed, probably because of the
coexpression in that compartment of Ant2 that may partially
compensate for the lack of Ant1. This effect may be ampliﬁed by the
higher number of mitochondria in the EOM, when compared to the
skeletal muscle [146].
4. Mouse models for the study of mtDNA defects
4.1. Transmitochondrial mice
Since the ﬁrst pioneering studies, almost 30 years ago, a great
effort has been devoted by the scientiﬁc community to the develop-
ment of mouse models to allow the investigation of segregation,
transmission and pathogenesis of human mtDNA mutations. The ﬁrst
step in the creation of transmitochondrial mice (mice carrying ectopic
mtDNA) were performed byWatanabe et al. [147] who used cytoplast
fusion technique to introduce a speciﬁc mitochondrial gene marker
into mice. Cybrids were obtained by fusing mouse mutagenized
melanoma cytoplasts carrying a mutation in the 16S rRNA, that
confers resistance to chloramphenicol (CAPR), with teratocarcinoma
stem cells. The selected cybrid clones were microinjected into
blastocysts of an inbred mouse strain. Analysis of the F1 generation
failed to clearly demonstrate transmission of the mtDNA mutation.
About 10 years later Jenuth et al. [148] developed another strategy to
investigate mitochondrial segregation in mouse by following the
heteroplasmic levels of two different naturally occurring mtDNA
polymorphisms in the NZB/BinJ and BALB/cByJ mouse strains. In this
case, cytoplasts obtained from the NZB or BALB derived zygote were
electrofused to a recipient one-cell embryo of the other type and, then,
the two cells embryowas transplanted in a pseudopregnantmother to
complete the development. From this study emerged that, in mouse,
the random segregation of mtDNA occurs in the early oogenesis and
that the number of segregating units is about 200 mtDNA molecules.
In addition, they observed an age related and a tissue speciﬁc
segregation pattern of the two different genomes, with NZB
segregating preferentially in liver and kidney, and BALB in spleen
and blood [149]. Conversely, when hepatocytes were cultured in vitro
and entered the proliferative stage, they reversed the genotype
selection, accumulating BALB mtDNA instead of NZB. These data
suggested the presence of unknown factors that confer selection to
different mitochondrial genotypes in a tissue or cell speciﬁc manner.
The BALB/NZB mtDNA heteroplasmic mice have been very useful as a
model for the modulation of mtDNA heteroplasmy by mitochondria-
targeted nucleases [150,151].
A ﬁrst proof that a mtDNA substitution has been successfully
maternally transmitted, was provided by Marchington et al. [152].
They generated heteroplasmic embryonic stem (ES) cells by fusing wt
(or CAPS) female ES cells with enucleated T3T cells carrying the CAPR
genotype. The CAPR genotype is conferred by a AÄT base substitution
at position 2379 in 16S rRNA gene of the mtDNA. The potential
pathogenicity of the CAPR genotype has been demonstrated by studies
on cybrids carrying more than 90% of the mutation that showed
respiratory deﬁciency [153]. Mutations have been reported in the 16SrRNA in patients affected by encephalomyopathy, myopathy and type
2 diabetes [154–157]. In all the patients examined, there was a marked
decrease in mitochondrial protein synthesis, probably due to an
alteration of the secondary structure of the rRNA, with a consequent
impairment of the OXPHOS. Although at low levels (about 6%), the
mutation was found in many tissues of the transmitochondrial
chimera mice.
Levy et al. showed that, by fusing enucleated CAPR cytoplasts with
R-6-G treated ES cells and by injecting the blastocysts with the derived
CAPR homoplasmic ES cells, they increased the levels of the mutation
in the analyzed tissues from 0% to 50%, with the highest amount found
in kidney [153].
The ﬁrst generation of transmitochondrial mice, carrying patho-
genic mutations and expressing abnormal phenotypes, was achieved
by Slight et al. and by Inoue et al. The ﬁrst group developed a mouse
with the CAPR mutation by fusing the enucleated CAPR 501-1 mouse
cell line with R-6-G treated ES CC99.3.1 cells [158]. The cybrids were
injected into B6 blastocyst and the resulting chimeric mice showed
the presence of cataracts. Electroretinogram (EGR) examination
showed loss of rods and cones without retinal degeneration. Female
chimeras transmitted the mutation to the next generation and about
50% of the CAPR mtDNAwas found in the pups. Some of the pups died
in utero and the ones born showed growth retardation, myopathy and
cardiomyopathy and eventually died after about 11 days. Sections of
skeletal muscle and heart revealed ﬁber degeneration and the
presence of abnormal mitochondria, resembling the features of
mitochondrial myopathy and cardiomyopathy. Nevertheless, a speciﬁc
characterization of the respiratory defect has been conducted only in
the culture cybrids carrying the mutation but not in the affected
tissues of the CAPR as a stable line could not be established.
Inoue et al. developed a transmitochondrial mouse model carrying
a mtDNA deletion of about 4.7 kb that could be maintained as a colony
[159]. To generate the mouse, enucleated cytoplast, derived from
deleted mtDNA (ΔmtDNA) cybrids, were electrofused into the mouse
zygote in a pro-nucleus stage embryos. After 24–48 h of in vitro
culture, the embryos where implanted in the oviduct of a pseudo-
pregnant female. The ΔmtDNA was successfully maternally trans-
mitted but the amount of the mutation found in the tissues of the
offspringwas never higher than 90%, probably due to a loss of the eggs
carrying the highest level of the deletion. Molecular analysis of the
mtDNA showed the presence of three different species, wt mtDNA,
ΔmtDNA and partially duplicated mtDNA, derived by the recombina-
tion of deleted and wt mtDNA during early embryogenesis. Unlike the
deleted mtDNA, the duplicated mtDNA molecules can be maternally
transmitted and either them or associated mtDNA deletions can cause
mitochondrial diseases [160,161]. Analysis of tissues in F1–F3 mice
showed the presence of RRF-like and a mosaic distribution of COX
negative ﬁbers. Examination of the single muscle ﬁbers showed that
only when the amount of the duplicated molecules was higher than
85% they became COX negative. The tissues most affected by the
presence of rearranged mtDNA were muscle, heart and above all
kidney. The mice died within 200 days of renal failure, the tissue with
the highest percentage of COX negative cells. Notably, the deleted
molecules did not escape the selection process during the early
embryo development.
Recent studies have demonstrated that in mice, the maternal
transmission of a mutation to the offspring is strictly related to the
pathogenicity of the mutation itself [162]. Fan et al. compared the
transmission rate of two mtDNA mutations with different pathogeni-
city. The ﬁrst onewas a base insertion in theND6 (ND6ins) gene coding
for a subunit of complex I that completely abolished its function. The
insertion caused a frameshift generating a premature stop codon. The
milder one was a missense mutation in COI gene, coding for a subunit
of complex IV that decreased its activity to 50% of wt. This same
mutation had been previously introduced in mice by Kasahara et al.,
who reported a 50% decrease in COX activity in tissues harbouring the
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cytoplast carrying both the ND6 and the COI mutation, with ES cells
devoid ofmitochondria. Interestingly, it was observed that the amount
of heteroplasmy of the ND6ins decreased in the female germ line until
the total loss of the mutation in 4 generations, whereas the COI
mutation persisted over time causing mitochondrial myopathy and
cardiac hypertrophy. Although the loss of mutated mtDNA molecules
has been documented in mammals [164–167], the time and the
modality leading to this process are still debated. Fan et al. [162]
provided evidence that the elimination of the mutated mtDNA occurs
even before the ovulation, when the number of proto-oocytes is
reduced by ROS-induced apoptosis. According to this theory, the
increased amount ofmutatedmtDNA in some oogoniawould generate
more ROS inducing a more selective elimination of these cells. Cree et
al. [168], instead, hypothesized that the elimination ofmutatedmtDNA
might occur during the rapid proliferation of mtDNA in the expanding
germ line through the loss of the segregating units, represented by the
mtDNA molecule itself. Moreover, an additional elimination of
deleterious molecules could occur during the time between the
implantation of the embryo and the resumption of mtDNA replication
or through an unequal distribution of mtDNA molecules during
cytokinesis. Although is still not clearwhen andhow this “puriﬁcation”
process takes place the current view is that the female germ line is
providedwith a natural ﬁlter to progressively eliminate the potentially
deleterious mtDNA that might affect the fecundity. Stewart et al.
reported a rapid and strong elimination of nonsynonymous changes in
protein-coding genes in mice carrying mtDNA point mutations
generated by a defective Pol γ [169]. Their data recapitulates the
“puriﬁcation” of human mtDNA polymorphisms during evolution and
the mechanisms of protection against disease [169].
5. Concluding remarks and future directions
Although lower organisms, such as yeast, ﬂies and worms have
provided important feedback about many basic mitochondrial
biochemical pathways, the marked evolutionary distance between
these species and humans does not allow for conclusive information
about the impact that mitochondrial defects might have in tissues or
organs. In contrast, mice have been proven to be suitable models to
study human disease both because of the high homology between
human and murine genes and because of the similarities in the
phenotypes developed. The development of animal models will
continue to shed light on the function of novel mitochondrial proteins
and on the function of already known ones. In addition, mousemodels
are now extensively characterized and represent valuable tools for the
test and implementation of therapeutic strategies. As an example, in
our laboratory we are taking advantage of a mouse model of COX
deﬁciency (Cox10/Mlc1f-Cre) to test the effect of increased mitochon-
drial proliferation on the onset and severity of the disease.
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